1 – 10 of 14
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort
(
- Contribution to journal › Article
- 2019
-
Mark
Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men
2019) In Prostate(
- Contribution to journal › Article
- 2018
-
Mark
Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model : An Individual Patient Data Meta-Analysis
(
- Contribution to journal › Article
- 2016
-
Mark
Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel
2016) In Journal of Urology(
- Contribution to journal › Article
- 2014
-
Mark
Emerging PSA-based tests to improve screening
(
- Contribution to journal › Scientific review
- 2013
-
Mark
Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?
(
- Contribution to journal › Article
- 2010
-
Mark
Impact of Recent Screening on Predicting the Outcome of Prostate Cancer Biopsy in Men With Elevated Prostate-Specific Antigen Data From the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden
(
- Contribution to journal › Article
- 2005
-
Mark
Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues
(
- Contribution to journal › Article
-
Mark
Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade
(
- Contribution to journal › Article
- 2003
-
Mark
Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies
(
- Contribution to journal › Article